StockDriftsStockDriftsDefinium Therapeutics, Inc. has 2 SEC filings in the last 90 days, latest: Announces positive Phase 3 Panorama study results for DT120 ODT (8-K, September 14, 2026). Each filing below is summarised from the document itself and links straight to the original on SEC EDGAR.
Definium Therapeutics reported positive topline data from its Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder, meeting all primary and key secondary endpoints.
Definium Therapeutics announced its DT120 ODT program for Major Depressive Disorder (MDD) received FDA Breakthrough Therapy designation, supported by positive Phase 3 results.